| Phase 15 trials |
|
Phase 1
|
NCT07625618 |
Sep → Dec 2024 |
liver disorder |
Wuhan Createrna Science and Technology Co., Ltd |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06543459 |
Aug → Sep 2024 overdue |
paroxysmal nocturnal hemoglobinuria |
Wuhan Createrna Science and Technology Co., Ltd |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05828472 |
Jan → Jun 2023 |
paroxysmal nocturnal hemoglobinuria |
Wuhan Createrna Science and Technology Co., Ltd |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05828485 |
Sep → Oct 2022 |
paroxysmal nocturnal hemoglobinuria |
Wuhan Createrna Science and Technology Co., Ltd |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05642585 |
May 2022 → Jun 2023 |
paroxysmal nocturnal hemoglobinuria |
Wuhan Createrna Science and Technology Co., Ltd |
Completed
|
No outcome recorded
|
| Phase 23 trials |
|
Phase 2
|
NCT06134414 |
Dec 2025 → Jul 2027 expected |
paroxysmal nocturnal hemoglobinuria |
Wuhan Createrna Science and Technology Co., Ltd |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06687174 |
Dec 2024 → Jun 2026 overdue |
IgA glomerulonephritis |
Wuhan Createrna Science and Technology Co., Ltd |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06050226 |
Jul 2023 → Apr 2024 |
paroxysmal nocturnal hemoglobinuria |
Wuhan Createrna Science and Technology Co., Ltd |
Completed
|
No outcome recorded
|
| Phase 2/31 trial |
|
Phase 2/3
|
NCT06933914 |
Nov 2024 → Dec 2026 expected |
paroxysmal nocturnal hemoglobinuria |
Wuhan Createrna Science and Technology Co., Ltd |
Recruiting
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT06932471 |
Aug 2024 → Dec 2025 overdue |
paroxysmal nocturnal hemoglobinuria |
Wuhan Createrna Science and Technology Co., Ltd |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06932744 |
Aug 2024 → Dec 2025 overdue |
paroxysmal nocturnal hemoglobinuria |
Wuhan Createrna Science and Technology Co., Ltd |
Recruiting
|
No outcome recorded
|